Region Skåne

Regions Skåne and Stockholm recommends Jyseleca among first choices when initiating JAK-inhibitors

Recommendation

As a result of the national tenders Regions Skåne and Stockholm recommends Jyseleca (filgotinib) or Xeljanz (tofacitinib) as first choices when initiating JAK-inhibitors to patients with RA and other arthritis disorders (for approved indications according to fass.se).

National tenders is a part of the governments strategy to be able to utilise innovations in a cost effective way. Following national tenders, Jyseleca is now recommended in Regions Skåne and Stockholm as a first choice for treatment of arthritis disorders:

Patients with rheumatoid disorders, including rheumatoid arthritis (RA), that has had inadequate effect of TNF-inhibitors (biosimilars)
When treating with JAK-inhibitors the cardiovascular risk profile should be considered
When treating with JAK-inhibitors, cost effectiveness should be considered. When initiating treatments filgotinib and tofacitinib are recommended as first choices, and upadacitinib is recommended as second choice.

References

References accessed online December 2022:

1. val av JAK-hämmare inom reumatologi, gastroenterologi och dermatologi (skane.se)
2. JAK-hämmare för behandling av måttlig till svår reumatoid artrit - Janusinfo.se.